Protocol Ledger

NCT03609216 · Phase II · ACTIVE NOT RECRUITING

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Interventional Phase II clinical trial protocol NCT03609216 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-10 Enrollment: 237 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03609216
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)237 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03609216
Protocol FieldVerified Registry Value
NCT IdentifierNCT03609216
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment237 participants (ACTUAL)
Registered Start Date2018-12-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03609216
Hospital Research SiteLocationSite Profile
Fairbanks Memorial HospitalFairbanks, AKOpen Hospital Dossier ->
Cancer Center at Saint Joseph'sPhoenix, AZOpen Hospital Dossier ->
Mercy Hospital Fort SmithFort Smith, AROpen Hospital Dossier ->
CHI Saint Vincent Cancer Center Hot SpringsHot Springs, AROpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI